Bendic Health Care Private Limited

Daploben-MS Tablet is a triple-combination oral anti-diabetic medicine designed for comprehensive management of Type 2 Diabetes Mellitus. It combines Dapagliflozin (SGLT2 inhibitor), Sitagliptin (DPP-4 inhibitor), and Metformin (biguanide) to deliver multi-pathway glycemic control—addressing insulin resistance, incretin deficiency, and renal glucose reabsorption in a single tablet.

Key Benefits & Uses:

• Improves fasting and post-prandial blood glucose control

• Reduces HbA1c through complementary mechanisms

• Low risk of hypoglycemia when used appropriately

• Supports weight neutrality or modest weight reduction

• Convenient once-daily combination therapy for better adherence

Why Choose Daploben-MS:

• Triple-action control for patients inadequately managed on dual therapy

• Simplifies diabetes management with a single tablet

• Manufactured under stringent quality standards by Bendic Healthcare Pvt. Ltd.

Ideal For:
Diabetologists, physicians, hospitals, and retail pharmacies seeking a dependable Dapagliflozin + Sitagliptin + Metformin tablet for advanced Type 2 diabetes management.